In contrast, bispecific CAR-T cells targeting both CD44 and CD133 achieved enhanced tumor regression and prolonged survival, underscoring the need for multitarget strategies to address CSC heterogeneity effectively.420 Furthermore, while CD133 remains a widely explored CSC surface marker, its expression is not restricted to malignant cells. This evidence concerns the gene PROM1 and neoplasm.